Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies

Journal of Clinical Oncology

Volumn 18, Issue 24, 2000, Pages 4086-4097

  Eckhardt, S G ^a   Baker, S D ^a   Britten, C D ^a   Hidalgo, M ^a   Siu, L ^a   Hammond, L A ^a   Villalona Calero, M A ^a   Felton, S ^a   Drengler, R ^a   Kuhn, J G ^a   Clark, G M ^a   Smith, S L ^a   MacDonald, J R ^a   Smith, C ^a   Moczygemba, J ^a   Weitman, S ^a   Von Hoff, D D ^a   Rowinsky, E K ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; CYTOTOXIN; IROFULVEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; ERYTHEMA; FATIGUE; FEMALE; HUMAN; KIDNEY TUBULE ACIDOSIS; MALE; MUSHROOM; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 0034671423     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.24.4086     Document Type: Article

References (27)

1. Preclinical evaluation of illudins as anticancer agents
2. Preclincal evaluation of illudins as anticancer agents: Basis for selective cytotoxicity
3. Structure-activity relationships of illudins: Analogs with improved therapeutic index
4. In vitro and in vivo studies on the anticancer activity of dehydroilludin M
5. Hydroxymethylacylfulvene (HMAF), an illudin derivative with superior antitumor properties
6. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines
7. Drug uptake and cellular targets of hydroxy methylacylfulvene (HMAF)
8. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, irofulven)
9. Structure and reactivity of illudins
10. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF)
11. waf expression
12. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells: Unusually high sensitivity in ERCC2 and ERCC3 DNA helicase-deficient mutants compared to other chemotherapeutic agents
13. Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells
14. Preclinical antitumor activity of 6-hydroxymethlacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S
15. Antitumor activity of 6-hydroxymethylacylfulvene (HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units
16. Efficacy of HMAF (MGI 114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents
17. Antitumor activity of MGI 114 against human ovarian and pancreatic tumor xenograft models
18. Antitumor activity of MGI 114 against two human prostate tumor xenograft models. Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy
19. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp 170 metastatic MV522 lung carcinoma xenograft
20. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft
21. Single and multiple-dose intravenous toxicity of MGI 114, a novel antitumor agent, in rats
22. Some practical improvements in the continual reassessment method for phase I studies
23. The continual reassessment method (CRM) for dose escalation in phase I trials in San Antonio does not result in more rapid study completion
24. Phase I clinical trial design in cancer drug development
25. Single and multiple-dose intravenous toxicity of MGI 114, a novel antitumor agent, in beagle dogs